Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL
OncLive,
Matthew S. Davids, MD, MMSc Treatment with acalabrutinib (Calquence)–based regimens led to long-term efficacy in patients with…
Matthew S. Davids, MD, MMSc Treatment with acalabrutinib (Calquence)–based regimens led to long-term efficacy in patients with…
Treatment options are distinct in their mechanisms, safety profiles, and implications for patients’ quality of life.
This study highlights one benefit of the integrated health system specialty pharmacy model for patients who are prescribed…
In a debate, experts discuss the importance of IGHV and TP53 mutational status in predicting response to novel therapies in…
Patients now have multiple options, including continuous therapy with BTK inhibitors and fixed-duration therapy with venetoclax-b…
Historical prognostic markers for chemoimmunotherapy have largely lost their clinically relevance in the context of targeted…
Though venetoclax-based regimens can produce high response rates in patients with chronic lymphocytic leukemia (CLL), disease…
/David A Litman, stock.adobe.com Alexandria Die Hemmung der Bruton-Tyrosinkinase (BTK) ist ein wirksamer Behandlungsansatz fr…
Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia (CLL) regardless of…
The first validated risk score to predict overall survival (OS) in patients with relapsed or refractory chronic lymphocytic…
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults in Western countries, with an estimated 20,720…
Javier Pinilla-Ibarz, MD, PhD, comments on the importance of patient-reported outcomes from the RESONATE-2 trial, as well as…
È stato da poco pubblicato sulla rivista Blood un aggiornamento delle linee guida di consenso del 2008 relative alla…
Mar 23, 2018 The International Workshop on Chronic Lymphocytic Leukemia recently published an update to its 2008 consensus…